Robert Riesenberg
Sage Group
15 Papers
14 Citations
Robert Riesenberg is an academic researcher from Sage Group. The author has contributed to research in topics: Medicine & Placebo. The author has an hindex of 5, co-authored 10 publications.
Chat about Author
Papers
Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials
Samantha Meltzer-Brody,Helen Colquhoun,Robert Riesenberg,C. Neill Epperson,Kristina M. Deligiannidis,David R. Rubinow,Haihong Li,Abdul J. Sankoh,Christine Clemson,Amy Schacterle,Jeffrey Jonas,Stephen Kanes +11 more
TL;DR: Braxanolone injection (formerly SAGE-547 injection), a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors, is assessed for the treatment of moderate to severe post-partum depression.
505
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial
Stephen Kanes,Helen Colquhoun,H. Gunduz-Bruce,Shane Raines,Ryan Arnold,Amy Schacterle,James J. Doherty,C. Neill Epperson,Kristina M. Deligiannidis,Robert Riesenberg,Ethan Hoffmann,David R. Rubinow,Jeffrey Jonas,Steven M. Paul,Samantha Meltzer-Brody +14 more
TL;DR: In women with severe post-partum depression, infusion of brexanolone resulted in a significant and clinically meaningful reduction in HAM-D total score, compared with placebo, which supports the rationale for targeting synaptic and extrasynaptic GABAA receptors in the development of therapies for patients with post- partum depression.
383
Trial of SAGE-217 in Patients with Major Depressive Disorder
H. Gunduz-Bruce,Christopher Silber,Inder Kaul,Anthony J. Rothschild,Robert Riesenberg,Abdul J. Sankoh,Haihong Li,Robert Lasser,Charles F. Zorumski,David R. Rubinow,Steven M. Paul,Jeffrey Jonas,James J. Doherty,Stephen Kanes +13 more
TL;DR: Administration of SAGE-217 daily for 14 days resulted in a reduction in depressive symptoms at day 15, and adverse events were more common in the Sage-217 group than in the placebo group.
Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program.
C. Neill Epperson,David R. Rubinow,Samantha Meltzer-Brody,Kristina M. Deligiannidis,Robert Riesenberg,Andrew D. Krystal,Kemi Bankole,Ming-Yi Huang,Haihong Li,Colville Brown,Stephen J. Kanes,Robert Lasser +11 more
TL;DR: Brexanolone is currently the only treatment specifically approved for postpartum depression in the United States, based on the results from one Phase 2 and two Phase 3 double-blind, randomized, controlled trials in the HUMMINGBIRD program as discussed by the authors .
44
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
Flor M. Munoz,Lawrence Sher,Charu Sabharwal,Alejandra Gurtman,Xia Xu,Nicholas Kitchin,Stephen Lockhart,Robert Riesenberg,Joanna M Sexter,Hanna Czajka,Grant Paulsen,Yvonne Maldonado,Emmanuel B. Walter,Kawsar R. Talaat,Janet A. Englund,Uzma N. Sarwar,Caitlin Hansen,Martha Iwamoto,Chris Webber,Luke Cunliffe,Benita Ukkonen,Silvina N Martínez,Barbara A. Pahud,Iona Munjal,Joseph B. Domachowske,Kena A. Swanson,Hua Ma,Kenneth Koury,Susan Mather,Claire M. Lu,Jing Zou,Xuping Xie,Pei Yong Shi,David A. Cooper,Özlem Türeci,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +37 more
TL;DR: A phase 1 dose-finding study and an ongoing phase 2-3 safety, immunogenicity, and efficacy trial of the BNT162b2 vaccine in healthy children 6 months to 11 years of age was conducted in this article .
32